These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36812659)

  • 21. ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines.
    Wikiniyadhanee R; Lerksuthirat T; Stitchantrakul W; Chitphuk S; Takeda S; Dejsuphong D
    Biomed Res Int; 2023; 2023():7891753. PubMed ID: 36794257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
    Cao K; Wang R; Li L; Liao Y; Hu X; Li R; Liu X; Xiong XD; Wang Y; Liu X
    Oncogene; 2024 Jan; 43(1):35-46. PubMed ID: 38007537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells.
    de Campos-Nebel M; Larripa I; González-Cid M
    Mutat Res; 2008 Nov; 646(1-2):8-16. PubMed ID: 18812179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
    Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
    Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
    Wang H; Zhang S; Song L; Qu M; Zou Z
    Oncogene; 2020 Apr; 39(14):2905-2920. PubMed ID: 32029902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
    Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
    Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
    Póti Á; Gyergyák H; Németh E; Rusz O; Tóth S; Kovácsházi C; Chen D; Szikriszt B; Spisák S; Takeda S; Szakács G; Szallasi Z; Richardson AL; Szüts D
    Genome Biol; 2019 Nov; 20(1):240. PubMed ID: 31727117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate.
    Nikolova T; Ensminger M; Löbrich M; Kaina B
    DNA Repair (Amst); 2010 Oct; 9(10):1050-63. PubMed ID: 20708982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51.
    Heijink AM; Stok C; Porubsky D; Manolika EM; de Kanter JK; Kok YP; Everts M; de Boer HR; Audrey A; Bakker FJ; Wierenga E; Tijsterman M; Guryev V; Spierings DCJ; Knipscheer P; van Boxtel R; Ray Chaudhuri A; Lansdorp PM; van Vugt MATM
    Nat Commun; 2022 Nov; 13(1):6722. PubMed ID: 36344511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel UCHL
    Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
    Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
    Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
    Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks.
    Murmann-Konda T; Soni A; Stuschke M; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2021 Jul; 867():503372. PubMed ID: 34266628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.